Abstract
Objectives. To evaluate the effect of aromatase inhibitors on bone mineral density (BMD) and risk of bone fractures in women over-70 with early breast cancer (EBC), and to verify usefulness of bisphosphonates. Methods. 26 elderly women aged 77.2 ± 5 ys candidate to adjuvant IAs (anastrazole 1 mg/die) for EBC were enrolled. Femoral and lumbar spine DEXA, and morphometric evaluation of vertebral bodies were performed in all patients and repeated after 1 year. 13 patients with T-score > -2 and without fractures (group A) received calcium (1000 mg/die) and 25-OH-D3 (800 UI/die). 13 patients with T-score ≤ -2 or T-score > -2 and vertebral fractures (group B) were given in addition risedronic acid (35 mg/week). Results. In group A, at 1-year follow-up, no patients showed modification of lumbar and femoral-neck BMD, while throcanter (Δ BMD: -0.021 ± 0.020, p <0.01) and total hip (Δ BMD: -0.011 ± 0.018, p <0.05) BMD decreased significantly. In group B BMD was stable in all femoral sites, while lumbar BMD significantly increased (Δ BMD L2-L4: + 0.029 ± 0.04, p <0.05). No patients developed vertebral or other fractures during the follow-up. Conclusions. Short/medium-term treatment with aromatase inhibitors in elderly women with EBC causes minimal detrimental impact on bone. Concomitant use of bisphosphonates like risedronic acid allows a safe use of aromatase inhibitors also in elderly patients.
| Original language | Italian |
|---|---|
| Pages (from-to) | 31-36 |
| Number of pages | 6 |
| Journal | Giornale di Gerontologia |
| Volume | 58 |
| Issue number | 1 |
| Publication status | Published - Feb 2010 |
Fingerprint
ASJC Scopus subject areas
- Ageing
- Geriatrics and Gerontology
Cite this
Terapia adiuvante con anastrazolo nella donna anziana con carcinoma mammario precoce : Rischio di frattura e ruolo protettivo del risedronato. / Fricia, T.; Sergi, Giuseppe; Lonardi, S.; Marin, S.; Falci, C.; Pintore, G.; Monfardini, S.; Coin, A.; Basso, U.; Perissinotto, E.; Enzi, G.; Manzato, E.
In: Giornale di Gerontologia, Vol. 58, No. 1, 02.2010, p. 31-36.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Terapia adiuvante con anastrazolo nella donna anziana con carcinoma mammario precoce
T2 - Rischio di frattura e ruolo protettivo del risedronato
AU - Fricia, T.
AU - Sergi, Giuseppe
AU - Lonardi, S.
AU - Marin, S.
AU - Falci, C.
AU - Pintore, G.
AU - Monfardini, S.
AU - Coin, A.
AU - Basso, U.
AU - Perissinotto, E.
AU - Enzi, G.
AU - Manzato, E.
PY - 2010/2
Y1 - 2010/2
N2 - Objectives. To evaluate the effect of aromatase inhibitors on bone mineral density (BMD) and risk of bone fractures in women over-70 with early breast cancer (EBC), and to verify usefulness of bisphosphonates. Methods. 26 elderly women aged 77.2 ± 5 ys candidate to adjuvant IAs (anastrazole 1 mg/die) for EBC were enrolled. Femoral and lumbar spine DEXA, and morphometric evaluation of vertebral bodies were performed in all patients and repeated after 1 year. 13 patients with T-score > -2 and without fractures (group A) received calcium (1000 mg/die) and 25-OH-D3 (800 UI/die). 13 patients with T-score ≤ -2 or T-score > -2 and vertebral fractures (group B) were given in addition risedronic acid (35 mg/week). Results. In group A, at 1-year follow-up, no patients showed modification of lumbar and femoral-neck BMD, while throcanter (Δ BMD: -0.021 ± 0.020, p <0.01) and total hip (Δ BMD: -0.011 ± 0.018, p <0.05) BMD decreased significantly. In group B BMD was stable in all femoral sites, while lumbar BMD significantly increased (Δ BMD L2-L4: + 0.029 ± 0.04, p <0.05). No patients developed vertebral or other fractures during the follow-up. Conclusions. Short/medium-term treatment with aromatase inhibitors in elderly women with EBC causes minimal detrimental impact on bone. Concomitant use of bisphosphonates like risedronic acid allows a safe use of aromatase inhibitors also in elderly patients.
AB - Objectives. To evaluate the effect of aromatase inhibitors on bone mineral density (BMD) and risk of bone fractures in women over-70 with early breast cancer (EBC), and to verify usefulness of bisphosphonates. Methods. 26 elderly women aged 77.2 ± 5 ys candidate to adjuvant IAs (anastrazole 1 mg/die) for EBC were enrolled. Femoral and lumbar spine DEXA, and morphometric evaluation of vertebral bodies were performed in all patients and repeated after 1 year. 13 patients with T-score > -2 and without fractures (group A) received calcium (1000 mg/die) and 25-OH-D3 (800 UI/die). 13 patients with T-score ≤ -2 or T-score > -2 and vertebral fractures (group B) were given in addition risedronic acid (35 mg/week). Results. In group A, at 1-year follow-up, no patients showed modification of lumbar and femoral-neck BMD, while throcanter (Δ BMD: -0.021 ± 0.020, p <0.01) and total hip (Δ BMD: -0.011 ± 0.018, p <0.05) BMD decreased significantly. In group B BMD was stable in all femoral sites, while lumbar BMD significantly increased (Δ BMD L2-L4: + 0.029 ± 0.04, p <0.05). No patients developed vertebral or other fractures during the follow-up. Conclusions. Short/medium-term treatment with aromatase inhibitors in elderly women with EBC causes minimal detrimental impact on bone. Concomitant use of bisphosphonates like risedronic acid allows a safe use of aromatase inhibitors also in elderly patients.
KW - Anastrazole
KW - Early breast cancer
KW - Elderly
KW - Osteoporosis
UR - http://www.scopus.com/inward/record.url?scp=77952400112&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952400112&partnerID=8YFLogxK
M3 - Articolo
VL - 58
SP - 31
EP - 36
JO - Giornale di Gerontologia
JF - Giornale di Gerontologia
SN - 0017-0305
IS - 1
ER -